| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BSX | Common Stock | Options Exercise | $0 | +4.15K | +1.52% | $0.00 | 277K | Feb 15, 2022 | Direct | F1 |
| transaction | BSX | Common Stock | Tax liability | -$53.6K | -1.22K | -0.44% | $44.01 | 275K | Feb 15, 2022 | Direct | |
| transaction | BSX | Common Stock | Sale | -$397K | -9.14K | -3.32% | $43.47 | 266K | Feb 15, 2022 | Direct | F2, F3 |
| transaction | BSX | Common Stock | Options Exercise | $76.5K | +12.2K | +4.58% | $6.28* | 278K | Feb 16, 2022 | Direct | F2 |
| transaction | BSX | Common Stock | Sale | -$533K | -12.2K | -4.38% | $43.70 | 266K | Feb 16, 2022 | Direct | F2, F4 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | BSX | Deferred Stock Units | Options Exercise | $0 | -4.15K | -50% | $0.00 | 4.15K | Feb 15, 2022 | Common Stock | 4.15K | Direct | F1, F5 | |
| transaction | BSX | Restricted Stock Units | Award | $0 | +17K | $0.00 | 17K | Feb 16, 2022 | Common Stock | 17K | Direct | F6, F7 | ||
| transaction | BSX | Stock Option (Right to Buy) | Award | $0 | +48.5K | $0.00 | 48.5K | Feb 16, 2022 | Common Stock | 48.5K | $44.19 | Direct | F8 | |
| transaction | BSX | Stock Option (Right to Buy) | Options Exercise | $0 | -12.2K | -100% | $0.00* | 0 | Feb 16, 2022 | Common Stock | 12.2K | $6.28 | Direct | F2, F9 |
| Id | Content |
|---|---|
| F1 | Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| F2 | The transactions reported in this Form 4 were effected pursuant to a pre-established Rule 10b5-1 trading plan. |
| F3 | Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.32 to $43.62, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F4 | Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.50 to $43.84, inclusive. The reporting person undertakes to provide upon request by the U.S.Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. |
| F5 | Shares of common stock will be issued to the reporting person in five equal annual installments beginning on February 15, 2019, the first anniversary of the date of grant. |
| F6 | Each restricted stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. |
| F7 | Shares of common stock will be issued to the reporting person in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |
| F8 | Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2023, the first anniversary of the date of grant. |
| F9 | Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. |
brennanpoa.txt